



Vitamin D3 Supplementation to Improve Fatigue in Patients with Advanced Cancer

Dragan Trivanović¹, Stjepko Pleština¹, Renata Dobriša Omtinjana¹, Lorena Honović², Ljiljana Jerinić³, Irena Hrstić³

¹General Hospital Pula, Department of Oncology Internal Medicine; ²University Hospital Centre Zagreb, Department of Oncology and Radiotherapy; ³University Hospital Centre Rijeka, Department of Oncology and Radiotherapy, Croatia

Abstract # 9097

Background: Fatigue is one of the most common symptoms of patients diagnosed with cancer.^{1,2} Vitamin D deficiency has been associated with an increased risk of mortality in oncology patients.^{3,4} We conducted a prospective vitamin D (cholecalciferol) supplementation study to analyse the response to oral D3 supplementation on fatigue in this population of chemo-naïve patients.

Methods: Eligibility criteria included life expectancy \geq 6 months, ECOG PS 0-3, low serum 25-hydroxyvitamin D3 at the time of diagnosis (using cutoff value of 32 ng/mL), and normal serum calcium level. Cancer related fatigue was measured with the Functional Assessment of Cancer Therapy Fatigue module (FACT-F).⁵ Patients were randomized to receive oral supplementation with 2,000 IU of Vitamin D3 daily for 3 months with standard cancer treatment or to continue standard treatment without vit D3 supplementation. Primary endpoint was changes in the FACT-F score. Secondary endpoints was: Improvement of vitamin D serum levels and safety

Results: 69 vit D deficient patients enrolled in the this study between November 2009 and November 2011 returned a baseline FACT-F. The mean serum 25(OH)D levels were 18.7 ng/ml (SD = 7.4) at baseline. Patients in experimental arm showed marked improvement from baseline in fatigue ($p < 0.05$) and vitamin D serum levels after 3 months ($p < 0.001$). There were significant difference in fatigue score in patients with experimental arm and control arm after 3 months of treatment ($p < 0.001$).

Conclusions: Vitamin D supplementation resulted in a significant increase in Fatigue score and serum 25(OH)D levels in vitamin D deficient patients. Fatigue improve rapidly but remain worse in control arm. The safety profile of vitamin D in combination with chemotherapy or BSC was acceptable.

Baseline Patient Characteristics

	Experimental arm	Control arm
Patients	34	35
Age, Years, Median	63	64
Female	13 (38 %)	14 (40 %)
ECOG 0-1	10 (29 %)	10 (29 %)
25(OH)D Median (ng/mL)	18.76	18.69
FACT-F score mean	32.6	32.9
Primary Cancer Site		
Lung	8 (24 %)	9 (25 %)
Colorectal	8 (24 %)	8 (23 %)
Breast	7 (20 %)	8 (23 %)
Other	11 (32 %)	10 (29 %)
Season of Blood Collection		
Summer-Autumn	16 (47 %)	16 (46 %)

Adverse Events (Any grade)

	Experimental arm	Control arm
Patients	34	35
Hypercalcemia	2 (6 %)	2 (6 %)
Pulmonary Embolism	0 (0 %)	1 (3 %)
Hematologic	18 (53 %)	17 (49 %)
Other Non-Hematologic	19 (56 %)	18 (51 %)
Fatigue	27 (80 %)	27 (78 %)

Results

Patients	N	Vitamin D change serum levels (SD)	FACT-F change score mean (SD)	Any AE gr III or IV
Baseline	34	13.56 (7.5)	3.8 (9.7)	7
Controls	35	-0.9 (6.6)	-2.3 (11.4)	7

References

1. Berger AJ, Abernethy AP, Aronson A, et al. Cancer-related fatigue. *J Palliat Care Hosp Netw* 2013;9(4):23
2. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACT) Scales, Version 4. Evanston, IL: Evanston Northwestern Healthcare, 1997
3. Portney KK, et al. Cancer-related fatigue: guidelines for evaluation and management. *Oncologist* 1998;3:1-10
4. Mok V, Adjei AA, Barlow D, et al. NCCN Practice Guidelines for Cancer Related Fatigue. *Oncology (Williston Park)* 2003;14:151-161
5. Austin P, Gordon S. Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. *2007 Arch Intern Med* 167(1):1750-1757
6. Wei Z, et al. Retrospective Study of Circulating 25-Hydroxyvitamin D Levels Predict Survival in Early-Stage Non-Small-Cell Lung Cancer Patients. *J Clin Oncol* 2007;25:479-8
7. Palmer C, Macgregor T, Grijalva S, et al. Serum 25-Hydroxyvitamin D Levels in early and advanced breast cancer. *J Clin Pathol* 2008;59:1334-1336
8. Freedman DM, Lubkin AG, Chang SC, et al. Prospective study of serum vitamin D and cancer mortality in the United States. *J Natl Cancer Inst* 2003;95:1594-1602

contact: Dragan Trivanovic, drivanovic@pula.gov.hr